Yıl: 2019 Cilt: 15 Sayı: 3 Sayfa Aralığı: 141 - 146 Metin Dili: İngilizce DOI: 10.5152/ejbh.2019.4890 İndeks Tarihi: 24-10-2020

Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer

Öz:
Objective: Breast cancer is the most common type of cancer and the leading cause of cancer-related deaths in women in Turkey. This study presentsthe characteristics of patients registered in National Breast Cancer Registry Program of Turkish Federation of Breast Diseases Societies.Materials and Methods: The registry contains 242 variables under 10 categories and 699 questions. Patients were recorded (online and offline)from nationwide breast centers around Turkey.Results: Twenty-thousand patients were registered between May 2005 and April 2017 at 36 centers. After data cleaning, 19,503 women wereincluded in the study. The median age at diagnosis was 51 [14-97]; 17.2% were younger than 40 and 37.2% were premenopausal; 13.6% werenulliparous. Breast conserving surgery rate was 39.3%. Histopathology was invasive ductal cancer in 77%. Majority of patients had stage II cancer(48.3%). Estrogen, progesterone and HER-2 receptor positivity rates in invasive breast cancer were 72.5%, 62.5% and 21.8%, respectively. Themean tumor diameter was 2.5±1.7 cm. During the mean 51.6 months of follow-up, the local/regional and systemic recurrence rates were 3.7% and5.2%, respectively; five and 10-year overall survival rates were 86% and 76%.Conclusion: Despite increasing number of screening centers and free-of-charge mammography (ages 40 to 69) and mobile screening systems inrecent years, a significant portion of patients were diagnosed at advanced stage due to lack of breast cancer awareness. In contrast with the studypublished 5 years ago, there was a decrease in the rate of pre-menopausal women and an increase in the breast conserving surgery.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. (PMID: 30207593) [CrossRef]
  • 2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-1953. (PMID: 30350310) [CrossRef]
  • 3. Ozmen V. Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). J Breast Health 2014; 10: 98- 105. (PMID: 28331652) [CrossRef]
  • 4. Ozmen V, Boylu S, Ok E, Canturk NZ, Celik V, Kapkac M, Girgin S, Tireli M, Ihtiyar E, Demircan O, Baskan MS, Koyuncu A, Tasdelen I, Dumanli E, Ozdener F, Zaborek P. Factors affecting breast cancer treatment delay in Turkey: a study from Turkish Federation of Breast Diseases Societies. Eur J Public Health 2015; 25: 9-14. (PMID: 25096257) [CrossRef]
  • 5. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377. (PMID: 1349978) [CrossRef]
  • 6. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410. (PMID: 1757079) [CrossRef]
  • 7. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International Variation in Female Breast Cancer Incidence and Mortality Rates. Cancer Epidemiol Biomarkers Prev 2015; 24: 1495-1506. (PMID: 26359465) [CrossRef]
  • 8. Porter P. "Westernizing" women's risks? Breast cancer in lower-income countries. N Engl J Med 2008; 358: 213-216. (PMID: 18199859) [CrossRef]
  • 9. Ries LG, Pollack ES, Young JL Jr. Cancer patient survival: Surveillance, Epidemiology, and End Results Program, 1973-79. J Natl Cancer Inst 1983; 70: 693-707. (PMID: 6572758)
  • 10. European Commission. European Network of Cancer Registries. Luxembourg, Office for Official Publications of the European Communities, 1995.
  • 11. Tuncer M, Özgül N, Olcayto EÖ, Gültekin M, Erdin B. Ulusal Kanser Programı 2009-2015, T.C. Sağlık Bakanlığı Kanserle Savaş Dairesi başkanlığı 2009: ISBN 978-975-590-285-2.
  • 12. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
  • 13. Siegel R.L., Miller K.D., and Jemal A. Cancer statistics. CA Cancer J Clin 2016; 66: 7-30. (PMID: 26742998) [CrossRef]
  • 14. Kayhan A, Gurdal SO, Ozaydin N, Cabioglu N, Ozturk E, Ozcinar B, Aribal E, Ozmen V. Successful first round results of a Turkish breast cancer screening program with mammography in Bahcesehir, Istanbul. Asian Pac J Cancer Prev 2014; 15: 1693-1697. (PMID: 24641392) [CrossRef]
  • 15. Kim J, Lee S, Bae S, Choi MY, Lee J, Jung SP, Kim S, Choe JH, Kim JH, Kim JS, Lee JE, Nam SJ, Yang JH. Comparison bet¬ween screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Res Treat 2012; 131: 527-540. (PMID: 22042364) [CrossRef]
  • 16. Újhelyi M, Pukancsik D, Kelemen P, Kovács E, Kenessey I, Udvarhelyi N, Bak M, Kovács T, Mátrai Z. Does breast screening offer a survival benefit? A retrospective comparative study of oncological outcomes of screen-detected and symptomatic early stage breast cancer cases. Eur J Surg Oncol 2016; 42: 1814-1820. (PMID: 27424787) [CrossRef]
  • 17. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736- 1747. (PMID: 21709140) [CrossRef]
  • 18. Çelebi F, Pilancı KN, Ordu Ç, Ağacayak F, Alço G, İlgün S, Sarsenov D, Erdoğan Z, Özmen V. The role of ultrasonographic findings to predict molecular subtype, histologic grade, and hormone receptor status of breast cancer. Diagn Interv Radiol 2015; 21: 448-453. (PMID: 26359880) [CrossRef]
  • 19. Alco G, Bozdogan A, Selamoglu D, Pilanci KN, Tuzlali S, Ordu C, Igdem S, Okkan S, Dincer M, Demir G, Ozmen V. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett 2015; 9: 1046-1054. (PMID: 25663855) [CrossRef]
APA Ozmen V, Ozmen T, DOĞRU V (2019). Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. , 141 - 146. 10.5152/ejbh.2019.4890
Chicago Ozmen Vahit,Ozmen Tolga,DOĞRU Volkan Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. (2019): 141 - 146. 10.5152/ejbh.2019.4890
MLA Ozmen Vahit,Ozmen Tolga,DOĞRU Volkan Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. , 2019, ss.141 - 146. 10.5152/ejbh.2019.4890
AMA Ozmen V,Ozmen T,DOĞRU V Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. . 2019; 141 - 146. 10.5152/ejbh.2019.4890
Vancouver Ozmen V,Ozmen T,DOĞRU V Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. . 2019; 141 - 146. 10.5152/ejbh.2019.4890
IEEE Ozmen V,Ozmen T,DOĞRU V "Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer." , ss.141 - 146, 2019. 10.5152/ejbh.2019.4890
ISNAD Ozmen, Vahit vd. "Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer". (2019), 141-146. https://doi.org/10.5152/ejbh.2019.4890
APA Ozmen V, Ozmen T, DOĞRU V (2019). Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. European Journal of Breast Health, 15(3), 141 - 146. 10.5152/ejbh.2019.4890
Chicago Ozmen Vahit,Ozmen Tolga,DOĞRU Volkan Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. European Journal of Breast Health 15, no.3 (2019): 141 - 146. 10.5152/ejbh.2019.4890
MLA Ozmen Vahit,Ozmen Tolga,DOĞRU Volkan Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. European Journal of Breast Health, vol.15, no.3, 2019, ss.141 - 146. 10.5152/ejbh.2019.4890
AMA Ozmen V,Ozmen T,DOĞRU V Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. European Journal of Breast Health. 2019; 15(3): 141 - 146. 10.5152/ejbh.2019.4890
Vancouver Ozmen V,Ozmen T,DOĞRU V Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. European Journal of Breast Health. 2019; 15(3): 141 - 146. 10.5152/ejbh.2019.4890
IEEE Ozmen V,Ozmen T,DOĞRU V "Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer." European Journal of Breast Health, 15, ss.141 - 146, 2019. 10.5152/ejbh.2019.4890
ISNAD Ozmen, Vahit vd. "Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer". European Journal of Breast Health 15/3 (2019), 141-146. https://doi.org/10.5152/ejbh.2019.4890